ArticleScientific reports2025
Hybrid gabor attention convolution and transformer interaction network with hierarchical monitoring mechanism for liver and tumor segmentation.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Multi-Scale Residual Gated Attention U-Net for Liver Tumor Segmentation.Journal of imaging informatics in medicine · 2026Article
- SLIC-Former: a superpixel-guided transformer framework for automatic liver segmentation in CT images.Scientific reports · 2026Article
- Pioneering efficient deep learning architectures for enhanced hepatocellular carcinoma prediction and clinical translation.World journal of gastrointestinal oncology · 2026Article
- SECT-Net: hybrid dual-decoder network with SE-convolution transformer for liver tumor segmentation.Frontiers in physiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Liver and tumor segmentation is an important technology for the diagnosis of hepatocellular carcinoma. However, most existing methods struggle to accurately delineate the boundaries of the liver and tumor due to significant differences in their shapes, sizes, and distributions, which leads to unclear segmentation of the liver contour and incorrect delineation of the lesion area. To address this gap, we propose a hybrid gabor attention convolution and transformer interaction network with hierarchical monitoring mechanism for liver and tumor segmentation, named HyborNet. Generally, the proposed HyborNet consists of a local and a global feature extraction branch. Specifically, the local feature extraction branch consists of several cascaded gabor attention convolutional blocks, each of which contains a multi-dimensional interactive attention module and a gabor convolutional module. In this way, fine-grained information about the liver and tumor can be extracted, which refines the edge details of the target area and accurately depicts the lesion area. The global feature extraction branch is constructed with a transformer model, which is capable of extracting coarse-grained information about the liver and tumor and accurately distinguishing them from similar tissues. Additionally, we propose a cross-attention-based dual-branch interaction module that adaptively fuses features from different perspectives to emphasize the target region, thereby enhancing the network's segmentation performance. Finally, a hierarchical monitoring mechanism is employed in the decoding stage, which provides additional feedback from deeper intermediate layers to optimize the segmentation results. Extensive experimental results demonstrate that HyborNet significantly outperforms other state-of-the-art models in liver and tumor segmentation tasks. The proposed model effectively enhances liver image segmentation accuracy, assisting doctors in making more precise diagnoses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.